Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.

Yoshida H, Kim YH, Ozasa H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Yamamoto T, Ajimizu H, Hirai T.

In Vivo. 2018 Nov-Dec;32(6):1587-1590. doi: 10.21873/invivo.11418.

2.

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

Tsuji T, Ozasa H, Aoki W, Aburaya S, Funazo T, Furugaki K, Yoshimura Y, Ajimizu H, Okutani R, Yasuda Y, Nomizo T, Uemasu K, Hasegawa K, Yoshida H, Yagi Y, Nagai H, Sakamori Y, Ueda M, Hirai T, Kim YH.

Mol Cancer Res. 2019 Jan;17(1):212-224. doi: 10.1158/1541-7786.MCR-18-0325. Epub 2018 Aug 31.

PMID:
30171175
3.

PD-L1 Expression in Small Cell Lung Cancer.

Yasuda Y, Ozasa H, Kim YH.

J Thorac Oncol. 2018 Mar;13(3):e40-e41. doi: 10.1016/j.jtho.2017.10.013. No abstract available.

4.

Nivolumab in non-small-cell lung cancer with EGFR mutation.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Funazo T, Hirai T.

Ann Oncol. 2018 Mar 1;29(3):777-778. doi: 10.1093/annonc/mdx745. No abstract available.

PMID:
29161357
5.

Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

Tsuji T, Sakamori Y, Ozasa H, Yagi Y, Ajimizu H, Yasuda Y, Funazo T, Nomizo T, Yoshida H, Nagai H, Maeno K, Oguri T, Hirai T, Kim YH.

Oncotarget. 2017 May 16;8(42):71805-71816. doi: 10.18632/oncotarget.17895. eCollection 2017 Sep 22.

6.

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

Yasuda Y, Nomizo T, Ozasa H, Funazo T, Tsuji T, Yoshida H, Sakamori Y, Nagai H, Handa T, Kubo T, Kim YH.

Mol Clin Oncol. 2017 Oct;7(4):677-680. doi: 10.3892/mco.2017.1373. Epub 2017 Aug 11.

7.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib.

Agatsuma N, Yasuda Y, Ozasa H.

J Thorac Oncol. 2017 Sep;12(9):e141-e143. doi: 10.1016/j.jtho.2017.04.028. No abstract available.

8.

Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

Yasuda Y, Nishikawa Y, Sakamori Y, Terao M, Hashimoto K, Funazo T, Nomizo T, Tsuji T, Yoshida H, Nagai H, Ozasa H, Hirai T, Kim YH.

Mol Clin Oncol. 2017 Aug;7(2):295-297. doi: 10.3892/mco.2017.1310. Epub 2017 Jun 29.

9.

EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Funazo T, Yasuda Y, Hirai T.

Anticancer Res. 2017 May;37(5):2721-2725.

PMID:
28476851
10.

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Yoshida H, Yagi Y, Sakamori Y, Nagai H, Hirai T, Kim YH.

Sci Rep. 2017 Mar 23;7:45124. doi: 10.1038/srep45124.

11.

Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.

Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Nakaoku T, Yagi Y, Tsuji T, Nomizo T, Mishima M.

Mol Clin Oncol. 2016 Jul;5(1):213-215. Epub 2016 May 6.

12.

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report.

Shima H, Ozasa H, Tsuji T, Ajimizu H, Nomizo T, Yagi Y, Sakamori Y, Nagai H, Minamiguchi S, Kim YH, Mishima M.

Mol Clin Oncol. 2016 May;4(5):715-718. Epub 2016 Mar 7.

13.

[A Case of Recurrent Gallbladder Cancer with a Complete Response to S-1 Alternate-Day Administration].

Eto R, Nakatsu H, Ozasa H, Shimizu R.

Gan To Kagaku Ryoho. 2016 Jan;43(1):111-3. Japanese.

PMID:
26809537
14.

Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115.

Kunii E, Ozasa H, Oguri T, Maeno K, Fukuda S, Uemura T, Takakuwa O, Ohkubo H, Takemura M, Niimi A.

Anticancer Res. 2015 Oct;35(10):5241-7.

PMID:
26408683
15.

Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma.

Tsuji T, Kim YH, Ozasa H, Sakamori Y, Nagai H, Ajimizu H, Yagi Y, Furukawa A, Haga H, Mishima M.

Respir Med Case Rep. 2015 May 15;15:48-50. doi: 10.1016/j.rmcr.2015.05.003. eCollection 2015.

16.

Trimethylamine generation in patients receiving hemodialysis treated with l-carnitine.

Ozasa H, Shimizu M, Koizumi A, Wakabayashi A, Yamazaki H.

Clin Kidney J. 2014 Jun;7(3):329. doi: 10.1093/ckj/sfu045. Epub 2014 May 16. No abstract available.

17.

Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed.

Sakamori Y, Kim YH, Yoshida H, Nakaoku T, Nagai H, Yagi Y, Ozasa H, Mishima M.

Mol Clin Oncol. 2015 Mar;3(2):334-340. Epub 2014 Nov 4.

18.

Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer.

Kunii E, Oguri T, Kasai D, Ozasa H, Uemura T, Takakuwa O, Ohkubo H, Takemura M, Maeno K, Niimi A.

Cancer Chemother Pharmacol. 2015 May;75(5):985-91. doi: 10.1007/s00280-015-2723-x. Epub 2015 Mar 14.

PMID:
25772757
19.

Citrulline increases cholesterol efflux from macrophages in vitro and ex vivo via ATP-binding cassette transporters.

Uto-Kondo H, Ayaori M, Nakaya K, Takiguchi S, Yakushiji E, Ogura M, Terao Y, Ozasa H, Sasaki M, Komatsu T, Sotherden GM, Hosoai T, Sakurada M, Ikewaki K.

J Clin Biochem Nutr. 2014 Jul;55(1):32-9. doi: 10.3164/jcbn.13-76. Epub 2014 Jun 20.

20.

Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.

Kim YH, Nishimura T, Ozasa H, Nagai H, Sakamori Y, Iwata T, Sunadome H, Nishimura T, Mishima M.

Chemotherapy. 2013;59(6):414-9. doi: 10.1159/000363731. Epub 2014 Jul 16.

PMID:
25034625
21.

A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study).

Hazama S, Nakamura Y, Tanaka H, Hirakawa K, Tahara K, Shimizu R, Ozasa H, Etoh R, Sugiura F, Okuno K, Furuya T, Nishimura T, Sakata K, Yoshimatsu K, Takenouchi H, Tsunedomi R, Inoue Y, Kanekiyo S, Shindo Y, Suzuki N, Yoshino S, Shinozaki H, Kamiya A, Furukawa H, Yamanaka T, Fujita T, Kawakami Y, Oka M.

J Transl Med. 2014 Apr 30;12:108. doi: 10.1186/1479-5876-12-108.

22.

Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells.

Ozasa H, Oguri T, Maeno K, Takakuwa O, Kunii E, Yagi Y, Uemura T, Kasai D, Miyazaki M, Niimi A.

Cancer Sci. 2014 Aug;105(8):1032-9. doi: 10.1111/cas.12447. Epub 2014 Jul 25.

23.

Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review).

Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M.

Biomed Rep. 2013 Sep;1(5):691-696. Epub 2013 Jul 22.

24.

The effect of starvation on blood stream cancer cell metastasis to the liver in rat after laparotomy.

Muraoka T, Shirouzu K, Ozasa H, Oka Y, Momosaki K, Iwakuma N, Tanaka K, Ishibashi N.

Kurume Med J. 2013;60(2):59-66. Epub 2013 Feb 3.

25.

Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer.

Kuriyama Y, Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M.

Case Rep Oncol. 2013 Aug 14;6(2):430-3. doi: 10.1159/000354756. eCollection 2013.

26.

Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.

Suzuki T, Ozasa H, Itoh Y, Zhan P, Sawada H, Mino K, Walport L, Ohkubo R, Kawamura A, Yonezawa M, Tsukada Y, Tumber A, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Schofield CJ, Miyata N.

J Med Chem. 2013 Sep 26;56(18):7222-31. doi: 10.1021/jm400624b. Epub 2013 Sep 5.

27.

High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.

Kim YH, Ozasa H, Nagai H, Sakamori Y, Yoshida H, Yagi Y, Nakaoku T, Mishima M.

J Thorac Oncol. 2013 Sep;8(9):e85-6. doi: 10.1097/JTO.0b013e31829cebbb. No abstract available.

28.

Combination phase II study of weekly paclitaxel and 5'-DFUR for unresectable or recurrent gastric cancer.

Yoshino S, Furuya T, Shimizu R, Ozasa H, Nishimura T, Fukuda S, Kawaoka T, Hazama S, Oka M.

Anticancer Res. 2013 Jun;33(6):2629-33.

PMID:
23749919
29.

Involvement of intermediate filament nestin in cell growth of small-cell lung cancer.

Takakuwa O, Maeno K, Kunii E, Ozasa H, Hijikata H, Uemura T, Kasai D, Ohkubo H, Miyazaki M, Oguri T, Niimi A.

Lung Cancer. 2013 Aug;81(2):174-9. doi: 10.1016/j.lungcan.2013.04.022. Epub 2013 May 23.

PMID:
23706418
30.

Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.

Kasai D, Ozasa H, Oguri T, Miyazaki M, Uemura T, Takakuwa O, Kunii E, Ohkubo H, Maeno K, Niimi A.

Anticancer Res. 2013 May;33(5):1935-40.

PMID:
23645741
31.

Cotton wool-like poly(lactic acid)/vaterite composite scaffolds releasing soluble silica for bone tissue engineering.

Obata A, Ozasa H, Kasuga T, Jones JR.

J Mater Sci Mater Med. 2013 Jul;24(7):1649-58. doi: 10.1007/s10856-013-4930-5. Epub 2013 Apr 20.

PMID:
23606191
32.

Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.

Takakuwa O, Oguri T, Maeno K, Yokoyama M, Hijikata H, Uemura T, Ozasa H, Ohkubo H, Miyazaki M, Niimi A.

Am J Hosp Palliat Care. 2013 Nov;30(7):726-9. doi: 10.1177/1049909112470020. Epub 2012 Dec 21.

PMID:
23264661
33.

Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues.

Oguri T, Ozasa H, Uemura T, Takakuwa O, Kunii E, Kasai D, Ohkubo H, Miyazaki M, Maeno K, Sato S.

Oncol Lett. 2012 Sep;4(3):571-575. Epub 2012 Jun 26.

34.

A case of carcinomatous meningitis despite prophylactic cranial irradiation in small cell lung cancer during treatment with amrubicin.

Oguri T, Uemura T, Kunii E, Ozasa H, Ohkubo H, Miyazaki M, Maeno K, Sato S.

Oncol Lett. 2012 Aug;4(2):305-306. Epub 2012 May 22.

35.

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type.

Tomita Y, Oguri T, Takakuwa O, Nakao M, Kunii E, Uemura T, Ozasa H, Miyazaki M, Maeno K, Sato S.

Oncol Lett. 2012 Feb;3(2):405-410. Epub 2011 Dec 1.

36.

Splenic artery ligation: A protection against hepatic ischemia/reperfusion injury in partially hepatectomized rats.

Irie T, Ito K, Ozasa H, Noda Y, Ikeda S, Tanaka S, Arii S, Horikawa S.

Hepatol Res. 2012 Aug;42(8):819-27. doi: 10.1111/j.1872-034X.2012.00989.x. Epub 2012 Apr 2.

PMID:
22469310
37.

C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.

Takakuwa O, Oguri T, Ozasa H, Uemura T, Kunii E, Kasai D, Miyazaki M, Maeno K, Sato S.

J Thorac Oncol. 2011 Nov;6(11):1826-32. doi: 10.1097/JTO.0b013e318229137d.

38.

Pathways of metastases from primary organs to the ovaries.

Yamanishi Y, Koshiyama M, Ohnaka M, Ueda M, Ukita S, Hishikawa K, Nagura M, Kim T, Hirose M, Ozasa H, Shirase T.

Obstet Gynecol Int. 2011;2011:612817. doi: 10.1155/2011/612817. Epub 2011 Sep 11.

39.

Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: findings from in vitro and ex vivo studies.

Ozasa H, Ayaori M, Iizuka M, Terao Y, Uto-Kondo H, Yakushiji E, Takiguchi S, Nakaya K, Hisada T, Uehara Y, Ogura M, Sasaki M, Komatsu T, Horii S, Mochizuki S, Yoshimura M, Ikewaki K.

Atherosclerosis. 2011 Nov;219(1):141-50. doi: 10.1016/j.atherosclerosis.2011.07.113. Epub 2011 Aug 4.

PMID:
21862012
40.

Proteasomal inhibition promotes ATP-binding cassette transporter A1 (ABCA1) and ABCG1 expression and cholesterol efflux from macrophages in vitro and in vivo.

Ogura M, Ayaori M, Terao Y, Hisada T, Iizuka M, Takiguchi S, Uto-Kondo H, Yakushiji E, Nakaya K, Sasaki M, Komatsu T, Ozasa H, Ohsuzu F, Ikewaki K.

Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):1980-7. doi: 10.1161/ATVBAHA.111.228478. Epub 2011 Aug 4.

PMID:
21817095
41.

Effect of sulfonylurea agents on reverse cholesterol transport in vitro and vivo.

Terao Y, Ayaori M, Ogura M, Yakushiji E, Uto-Kondo H, Hisada T, Ozasa H, Takiguchi S, Nakaya K, Sasaki M, Komatsu T, Iizuka M, Horii S, Mochizuki S, Yoshimura M, Ikewaki K.

J Atheroscler Thromb. 2011;18(6):513-30. Epub 2011 Jun 3.

42.

Over-expression of MDR1 in amrubicinol-resistant lung cancer cells.

Takakuwa O, Oguri T, Ozasa H, Uemura T, Kasai D, Miyazaki M, Maeno K, Sato S.

Cancer Chemother Pharmacol. 2011 Sep;68(3):669-76. doi: 10.1007/s00280-010-1533-4. Epub 2010 Dec 3.

PMID:
21128075
43.

Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo.

Nakaya K, Ayaori M, Uto-Kondo H, Hisada T, Ogura M, Yakushiji E, Takiguchi S, Terao Y, Ozasa H, Sasaki M, Komatsu T, Ohsuzu F, Ikewaki K.

Atherosclerosis. 2010 Nov;213(1):135-41. doi: 10.1016/j.atherosclerosis.2010.07.024. Epub 2010 Jul 27.

PMID:
20723893
44.

ABCC11/MRP8 confers pemetrexed resistance in lung cancer.

Uemura T, Oguri T, Ozasa H, Takakuwa O, Miyazaki M, Maeno K, Sato S, Ueda R.

Cancer Sci. 2010 Nov;101(11):2404-10. doi: 10.1111/j.1349-7006.2010.01690.x.

45.

Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.

Hamada S, Suzuki T, Mino K, Koseki K, Oehme F, Flamme I, Ozasa H, Itoh Y, Ogasawara D, Komaarashi H, Kato A, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N.

J Med Chem. 2010 Aug 12;53(15):5629-38. doi: 10.1021/jm1003655.

PMID:
20684604
46.

The remarkable solvent effect on Zn(OAc)2-catalyzed hydrosilylation of ketones.

Ozasa H, Kondo K, Aoyama T.

Chem Pharm Bull (Tokyo). 2010 Jul;58(7):989-90.

47.

Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages.

Uto-Kondo H, Ayaori M, Ogura M, Nakaya K, Ito M, Suzuki A, Takiguchi S, Yakushiji E, Terao Y, Ozasa H, Hisada T, Sasaki M, Ohsuzu F, Ikewaki K.

Circ Res. 2010 Mar 5;106(4):779-87. doi: 10.1161/CIRCRESAHA.109.206615. Epub 2010 Jan 14.

PMID:
20075335
48.

Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens.

Takakuwa O, Oguri T, Maeno K, Ozasa H, Iwashima Y, Miyazaki M, Kunii H, Takano Y, Mori T, Sato S, Ueda R.

Oncol Lett. 2010 Jan;1(1):147-150. Epub 2010 Jan 1.

49.
50.

Small-cell lung cancer arising after chemotherapy for a patient with lymphoma of pulmonary mucosa-associated lymphoid tissue-a case report.

Nakao M, Oguri T, Maeno K, Kusumoto S, Ota C, Takakuwa O, Uemura T, Ozasa H, Iwashima Y, Miyazaki M, Kutsuna T, Nakamura A, Inagaki H, Sato S, Ueda R.

Gan To Kagaku Ryoho. 2009 Oct;36(10):1711-4.

PMID:
19838033

Supplemental Content

Support Center